Published in final edited form as:

ACS Chem Biol. 2011 July 15; 6(7): 753–760. doi:10.1021/cb2000378.

Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin

Patrick J. Knerr^{1,#}, Apostolia Tzekou^{3,#}, Daniel Ricklin³, Hongchang Qu³, Hui Chen³, Wilfred A. van der Donk^{1,2,*}, and John D. Lambris^{3,*}

¹ Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, IL 61801, Phone 217-244-5360, Fax 217-244-8533

² Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, IL 61801, Phone 217-244-5360, Fax 217-244-8533

³ Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, Phone 215-746-5765, Fax 215-573-8738

Abstract

Disulfide bonds are essential for the structural stability and biological activity of many bioactive peptides. However, these bonds are labile to reducing agents, which can limit the therapeutic utility of such peptides. Substitution of a disulfide bond with a reduction-resistant cystathionine bridge is an attractive means of improving stability while imposing minimal structural perturbation to the peptide. We have applied this approach to the therapeutic complement inhibitor compstatin, a disulfide-containing peptide currently in clinical trials for age-related macular degeneration, in an effort to maintain its potent activity while improving its biological stability. Thioether-containing compstatin analogues were produced via solid-phase peptide synthesis utilizing orthogonally-protected cystathionine amino acid building blocks and solid-supported peptide cyclization. Overall, the affinity of these analogues for their biological target and potent inhibition of complement activation were largely maintained when compared to those of the parent disulfide-containing peptides. Thus, the improved stability to reduction conferred by the thioether bond makes this new class of compstatin peptides a promising alternative for therapeutic applications. Additionally, the versatility of this synthesis allows for exploration of this disulfide-to-thioether substitution in a variety of other therapeutic peptides.

Introduction

Disulfide bonds play a critical role in the structural stability of peptides and proteins (1). Intricate conformations enforced by cyclic disulfide networks are associated with the potent biological activities of a variety of peptide natural products such as the conotoxins (2), cyclotides (3) and defensins (4). In the case of many bioactive peptides, the structural constraint introduced by disulfide cyclization has been demonstrated to improve resistance to proteolysis and reduce the entropic cost of binding to their targets (5, 6). However, the lability of the disulfide bond to intra- and extracellular reducing agents (7–9) can reduce the biological activity of disulfide-containing peptides and limit their usefulness as therapeutics.

*These authors, to whom correspondence should be addressed, shared the supervision of this study: vddonk@illinois.edu, lambris@upenn.edu.

#These authors contributed equally to this work.

Supporting Information Available. General materials and methods, synthetic procedures and characterization for synthetic compounds 6–17, effects of oxidation/reduction on the activity of peptides 4 and 5, and GC/MS procedures and chromatograms. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

To address this concern, substitution of the disulfide bond in bioactive peptides with a variety of different moieties has been explored, including the use of diselenide (10, 11), lactam (12, 13), carba (14–16) and thioether bridges (17, 18). A disulfide-to-thioether substitution utilizing a cystathionine (Cth) bridge is particularly attractive, since it involves the substitution of only a single atom (-S- to -CH₂-) and results in a carbon-sulfur bond stable to reduction with minimal structural perturbation. Synthetic replacement of disulfides with thioethers has produced analogues of vasopressin (19), oxytocin (20), anti-cardiolipid antibody binders (21) and VCAM/VLA-4 antagonists (22). However, as evidenced by lack of recent literature describing Cth-containing peptides, a higher-yielding and more versatile synthetic strategy is needed to allow greater access to these cyclic structures.

Cth is the methylene homologue of lanthionine, found in the lantibiotic family of natural products (23, 24). As such, the considerable body of work on the chemical synthesis of lanthionine-containing cyclic peptides, including lactosin S (25), bis(desmethyl)lactacin 3147 A2 (26), and fragments of nisin (27, 28) and subtilin (29, 30), is directly applicable to the synthesis of Cth analogues of disulfide-bridged peptides. Additionally, the structural constraint associated with cyclic lanthionines has been utilized to improve the activity and/or stability of bioactive peptides, including enkephalin (18), angiotensin (31), luteinizing hormone release hormone (32) and somatostatin (33). Thus, incorporation of cyclic thioether-containing amino acids is a valuable approach to the development and optimization of therapeutic peptides, and improved methods of constructing such compounds have application to a wide variety of biological problems.

Compstatin (I[CVVQDWGHHRC]T-NH₂) is a 13-residue, disulfide-containing peptide inhibitor of complement activation that was originally discovered via screening of a phage-display library (34). Compstatin inhibits the proteolytic activation of complement component C3 to the anaphylatoxin C3a and the opsonin C3b by C3 convertase complexes (Figure 1a) via direct binding to C3 as well as C3b (35–37). The central role of C3 and its proteolytic fragments in all complement initiation and amplification pathways makes compstatin an attractive potential therapeutic for the treatment of pathologies involving inappropriate activation of the complement system (35, 38), including a variety of autoimmune, inflammatory, and neurodegenerative diseases as well as sepsis, hemodialysis-associated thrombosis, heart attack, stroke and burn injuries. In particular, compstatin has shown promising activity in treating early forms of age-related macular degeneration and is currently in clinical trials for the treatment of this disease that constitutes a major cause of blindness in the elderly (39).

Early work has shown that the activity of compstatin is dependent on disulfide formation between cysteine residues at positions 2 and 12, which enforces the cyclic conformation critical for binding C3 (36). Either reduction-alkylation of the disulfide bond or replacement of the two cysteine residues with alanine results in complete loss of C3 binding and complement inhibition (34). Furthermore, cyclization protects compstatin from proteolytic degradation in human blood (40). Extensive structure-activity relationship studies have resulted in derivatives with up to 1000-fold improvement in potency when compared to the original compstatin sequence (35, 41–43). Yet the increasing use of compstatin in both systemic and local (e.g. intravitreal) clinical applications also puts new demands on pharmacokinetic properties such as metabolic stability. Here, we report the synthesis of a series of compstatin analogues **2**, **3** and **5** (Figure 1b) containing a reduction-resistant Cth bridge in place of disulfide, which maintain potent complement inhibitory activity and strong affinity for C3b.

Results and Discussion

Cth building block synthesis

We desired a versatile and high-yielding synthetic strategy to produce a family of Cth-containing compstatin analogues, which could also be applied to the synthesis of other Cth-containing peptides. In this regard, we adopted a 9H-fluorenylmethoxycarbonyl (Fmoc)-based solid-phase peptide synthesis (SPPS) that was modified from the approach used by Vederas and coworkers for the total synthesis of lantibiotics (25, 26). This strategy involved the synthesis of two enantiomerically pure, orthogonally-protected LL-Cth building blocks, representing the two possible sulfur-to-methylene substitutions from the parent disulfide, followed by solid-supported peptide assembly and cyclization. This building block approach allows for complete positional freedom for the placement of the Cth bridge within the cyclic peptide. Construction of Cth building block **11** (Scheme 1) proceeded in high yield via a convergent synthesis. Phase-transfer condensation (44) of Fmoc- and *tert*-butyl ester-protected L-cysteine **7**, derived from L-cystine, with allyloxycarbonyl (Alloc)- and allyl ester (OAll)-protected γ -bromo-L-aminobutyrate **9**, derived from L-homoserine, yielded the protected Cth building block **10**. The *tert*-butyl ester of **10** was subsequently removed to reveal the free carboxyl group in **11** necessary for SPPS. Synthesis of the other Cth isomer **17** (Scheme 2) was similarly performed via phase-transfer condensation of γ -bromoaminobutyrate derivative **13** with cysteine derivative **15**.

The stereochemical purity and absolute confirmation of the synthesized LL-Cth building blocks was assessed via chiral gas chromatography/mass spectrometry (GC/MS) using a Varian CP-Chirasil-L-Val column (Supporting Information). Compound **17** was globally deprotected and derivatized as the pentafluoropropionamide methyl ester (25, 45). Comparison of this compound with derivatized standards of LL- and DL-cystathionine confirmed the expected LL-configuration of the synthetic Cth building block with no detectable epimerization of the enantiomerically pure starting materials during synthesis.

Peptide synthesis

Three Cth-containing compstatin analogues (**2**, **3** and **5**) were prepared. Peptides **2** and **3** represent the two possible Cth analogues of the second-generation compstatin derivative 4W9A (control peptide **1**, Figure 1b) (36), with the Cth-based thioether bridge replacing the original Cys2-Cys12 disulfide bond. Our initial assessment of binding data with peptides **1**–**3** (see kinetic analyses below) indicated that the location of the sulfur atom closer to the *N*-terminus, as in **3** which results from building block **17**, yields a more potent complement inhibitor. Based on those results, we used **17** in the synthesis of analogue **5**, which includes three additional mutations (Trp⁴/Trp(Me), Gly⁸/Sar, and Thr¹³/*N*-Melle) found in the most active compstatin sequence reported to date, Compstatin 20 (control peptide **4**, Figure 1b) (41).

Construction of compstatin analogues **2**, **3** and **5** (Scheme 3) utilized Fmoc-based SPPS on Rink amide AM resin and 2-(6-chloro-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethylammonium hexafluorophosphate (HCTU) as the coupling reagent. As reported for the synthesis of the lanthionine-containing peptide bis(desmethyl)lacticin 3147 A2 (26), intermolecular coupling between the distal ends of two resin-bound lanthionine residues becomes problematic during cyclization when using resin loadings greater than 0.3 mmol/g. Therefore, in order to promote the desired intramolecular cyclization, resin loading was reduced to 0.2 mmol/g by coupling a substoichiometric amount of the Cth building block, followed by acetylation the remaining free resin sites with acetic anhydride (Materials and Methods). After coupling of the remaining residues inside the incipient cystathionine ring, the allyl protecting groups of the Cth residue were removed with Pd(PPh₃)₄ and PhSiH₃, and the *N*-terminal Fmoc group

was removed with piperidine. Cyclization of this deprotected resin-bound fragment **18** was promoted with (benzotriazole-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxy-7-azabenzotriazole (HOAt) and diisopropylethylamine. Coupling of the *N*-terminal isoleucine, Fmoc removal, amine acetylation and trifluoroacetic acid-promoted global deprotection/resin cleavage yielded the crude compstatin analogues, which were purified by reversed-phase highperformance liquid chromatography (RP-HPLC). The pure peptides were obtained with average overall yields of 2.4–5.0%, or 88–90% per step over 29 steps. Peptide **5** had the lowest overall yield, presumably due to difficulty in coupling the Cth building block immediately after a sterically demanding *N*-methyloisoleucine residue.

Chiral GC/MS was again utilized in order to confirm that the LL-stereochemistry of the Cth building blocks was maintained during compstatin analogue synthesis (Supporting Information). Peptide **5** was hydrolyzed in refluxing 6 M HCl, and the resulting amino acids were derivatized as the pentafluoropropionamide methyl esters and compared to the derivatized LL- and DL-cystathionine standards as described above. The vast majority of the derivatized cystathionine hydrolyzed from **5** contained the appropriate LL-configuration, confirming that the Cth building blocks are configurationally stable to the basic conditions employed during SPSS.

Kinetic analyses

The resulting Cth-containing compstatin analogues were then assayed to determine their affinity for C3b and their effectiveness in inhibiting complement activation. Kinetic characterization of the interaction of each compstatin analogue with C3b was performed using surface plasmon resonance (SPR). Biotinylated C3b was site-specifically captured on a streptavidin-coated sensor chip to prevent surface heterogeneity (38, 42). A kinetic ranking of the compstatin analogues at 1 μ M (Figure 2) indicated that the association and dissociation profiles of peptide **3** were the most comparable to those of its corresponding control peptide **1**. Peptide **2**, on the other hand, displayed a much faster dissociation rate compared to **1**. In the case of Compstatin 20, analogue **5** showed a similar association but faster dissociation rate than the corresponding control peptide **4**.

To further characterize and quantitate the relationship between the structure and activity of these compounds, we performed a full kinetic analysis. The slow dissociation rate constant of the current lead compstatin sequence **4** (41) would require long assay time to allow the signal to reach baseline level before the subsequent injection or the use of regeneration solutions that remove residual peptide, yet may harm the activity of C3b. We therefore opted for a single-cycle kinetics approach (46), which allows for kinetic characterization of interactions with slow dissociation rates in a shorter period of time than does the traditional multi-cycle approach (40). This approach was used for all peptides, so as to enable us to make direct comparisons of the acquired results. Importantly, all compounds showed a binding response that could be fitted to a 1:1 binding model. The single-cycle kinetics analysis showed fast association and dissociation rates for compounds **1**, **2** and **3**, and fast association but slower dissociation for compounds **4** and **5** (Figure 3, Table 1). The compounds mainly differ in their dissociation rates, whereas the association rate remained rather constant within the corresponding series of analogues. The resulting binding affinity is therefore mainly defined by the changes in k_d . In particular, peptide **2** displayed a 6-fold faster dissociation and a 6-fold reduced affinity when compared to control peptide **1**. Peptide **3**, on the other hand, had a slightly slower association rate (1.2-fold) and slightly faster dissociation rate (1.4-fold), yielding a ~1.6-fold lower affinity for C3b when compared to peptide **1**. Finally, compound **5** displayed a comparable association rate but a ~3-fold faster dissociation rate than the corresponding control peptide **4**, and thus a ~3.8-fold lower affinity for C3b. Importantly, the kinetic parameters for the control peptides **1** and **4** were

very similar to those published previously (40, 41). The largely stable association rate constants within each compound series suggest that the cystathionine modification had little effect on complex formation with C3b and appears to maintain the ability of compstatin peptides to change between the distinct solution and bound conformers (36, 41). However, the slightly changed geometry between a disulfide and a thioether bridge may have influenced the exact positioning of key residues such as the tryptophan derivatives at position 4 and 7, thereby affecting the complex stability as measured by k_d . This effect appears more pronounced in **5**, as the mutations made in control peptide **4** better tailored the peptide to the binding site. Importantly, our kinetic data clearly show that thioether-bridged analogues of compstatin show high binding affinities in the range of the compound currently in clinical trials (1Me-Trp⁴; $K_D = 11$ nM) (42).

Complement inhibition assays

The biological activity of the Cth-containing compounds was also compared to that of their corresponding disulfide-containing control peptides (Figure 4, Table 1). The ability of these compounds to inhibit antigen/antibody-induced complement activation was assessed by measuring the resulting reduction in C3b deposition on an ELISA plate when compared to a control well with no peptide. The percentage inhibition was then plotted against the peptide concentrations and fitted to a logistic dose-response function. These assays yielded results consistent with the data obtained in the kinetic assays. Again, peptide **2** was identified as the least active analogue, thereby confirming the unfavorable effect of sulfur-to-methylene substitution on the C-terminal side of the original disulfide. In both series, the thioether-containing peptides **3** and **5** showed a decreased inhibitory activity by a factor of only 2 when compared to their parent disulfide-linked peptides **1** and **4**, respectively (Table 1). In agreement with previous studies, these results show a good correlation between the binding affinity for C3b and the ability to inhibit complement activation. Importantly, the combined analyses also confirm thioether-restricted compstatin analogues as potent complement inhibitors.

Effect of oxidation and reduction on peptide activity

The resistance of the cyclic structure of the Cth-containing peptide **5** to reductive treatment and, conversely, the reductive lability of the corresponding disulfide-linked analogue **4** was confirmed by incubating the peptides with 500-fold molar excess of the reducing agent tris(2-carboxyethyl)-phosphine hydrochloride (TCEP-HCl) and subsequent analysis by mass spectrometry (Supporting Information). In order to confirm that recent compstatin analogues with largely increased potency and affinity still depend on an intact ring structure, we subjected the reduced-alkylated peptide **4** to binding and complement inhibition analysis as described above. This analysis is necessary in the context that analogues containing sarcosine instead of alanine at position 9 (including peptides **4** and **5**) have been implied to form a bound-like conformation in solution (41) that may have rendered maintenance of the disulfide less important. However, consistent with previous analogues (40), peptide **4** was rendered essentially inactive by the reduction process (Supporting Information), thereby confirming the importance both of the cyclic structure and of reductive stability. Whereas cyclic, *N*-acetylated compstatin analogues have previously been shown to exert high plasma stability under normal conditions (40), there are a variety of complement-related diseases that trigger changes in the reductive status of blood. For example, compstatin has shown promise as an organ-protecting agent in models of bacterial sepsis (47), but this pathology also involves a large increase in the plasma levels of thioredoxin that may endanger the disulfide structure (48). Similarly, complement inhibition by compstatin has large potential in hemolytic conditions such as paroxysmal nocturnal hemoglobinuria (38) or hemodialysis-induced side effects (49), during which the large reservoir of reduced glutathione (GSH) in erythrocytes (1–3 mM) is released that increases the plasma pool of GSH (50, 51). In these

compstatin-relevant therapeutic applications, protection of the peptide against reduction may therefore become even more important.

While thioethers are inert to reductive cleavage, their lability to metabolic oxidation is well documented, especially in the case of methionine in peptide and protein drugs (52, 53). In addition, thioether oxidation has been shown to severely decrease the activity of the lantibiotic nisin (54), although the lantibiotic actagardine contains an enzymatically-oxidized methyllanthionine bridge important for full activity (55). In our hands, the Cth-containing building blocks and peptides appear stable to spontaneous oxidation during synthesis, purification, biological testing and storage. However, to probe the effect of thioether oxidation on peptide binding and inhibitory activities, we exposed peptides **4** and **5** to conditions that allow selective oxidation of Cth to the corresponding sulfoxide by hydrogen peroxide (Supporting Information). Oxidation of peptide **5** lead to a mass shift of +16 Da while peptide **4** was largely unaffected by the treatment. As expected, the oxidative treatment of peptide **4** did not significantly affect its inhibitory potency ($\Delta IC_{50} < \text{factor } 2$). While Cth-oxidation of peptide **5** did induce some loss in both binding affinity and inhibition activity (4–6-fold), the oxidized peptide was still a highly potent inhibitor with a K_D below 100 nM (Supplementary Information).

Conclusion

We describe here the chemical synthesis of analogues of the complement inhibitor compstatin with a reduction-stable thioether bond in place of the reduction-labile disulfide bond. This modification was installed via a versatile and high-yielding solid-phase synthesis utilizing orthogonally-protected cystathionine building blocks. Furthermore, we have characterized the structure-activity relationships of these cystathionine-containing analogues and the disulfide-bonded parent peptides. Our results indicate that the position of the sulfur atom within the thioether bridge has consequences for activity, as δ -Cth-containing analogues largely maintained the binding and inhibitory properties of the disulfide parent but γ -Cth-containing analogues did not. In comparing potential metabolic alterations of these compounds, reduction of the disulfide bond had a much more deleterious effect on potency than potential oxidation of the cystathionine bridge, thereby underscoring the benefit of the substitution in this context. More generally, the impact of peptide-based drugs continues to grow, and many of these compounds contain disulfide bonds (56, 57). The versatile nature of the synthesis described here allows for the production of a wide variety of cyclic Cth-containing peptides in order to probe the effects of disulfide substitution on the activity and stability of other therapeutic peptides.

Materials and Methods

Synthesis of peptides **2**, **3** and **5** via SPPS

Fmoc-protected Rink amide AM resin (0.6 mmol/g loading) was swelled in dimethylformamide (DMF) for 20 min and Fmoc-deprotected with 20% piperidine in DMF (2×10 min). The first amino acid (Fmoc-Thr-OH for **2** and **3**, Fmoc-*N*-Me-Ile-OH for **5**; 4 equiv to resin) was pre-activated in the presence of HCTU (4 equiv) and diisopropylethylamine (8 equiv) in DMF for 5 min, then coupled to the resin for 1 h via agitation with N_2 . The Fmoc group was then removed. In order to prevent interstrand dimerization upon attempted cyclization, the resin loading was manually reduced to 0.15 mmol/g by reacting a pre-activated solution of **11** or **17** (0.25 equiv to resin), HCTU (0.25 equiv) and diisopropylethylamine (2 equiv) in DMF with the resin-bound peptide for 3 h. The remaining free resin sites were acetylated with a solution of 1:1:3 acetic anhydride/diisopropylethylamine/DMF for 30 min, yielding a negative Kaiser test.

After resin-loading modification, the resin-bound peptide was Fmoc-deprotected with 20% piperidine in DMF (2×10 min), the reaction vessel drained and the resin washed with DMF and CH_2Cl_2 . Appropriately side chain-protected Fmoc-amino acids (4 equiv with respect to the reduced-loading resin) were pre-activated in the presence of HCTU (4 equiv) and diisopropylethylamine (8 equiv) in DMF for 5 min, and then coupled to the deprotected resin for 45–60 min. The reaction vessel was drained and the resin washed with DMF and CH_2Cl_2 . A negative Kaiser test confirmed completed couplings.

Following the coupling of Fmoc-Val-OH to the resin-bound peptide, a solution of $\text{Pd}(\text{PPh}_3)_4$ (1 equiv to the reduced-loading resin) and PhSiH_3 (10 equiv) in 1:1 DMF/ CH_2Cl_2 was added to the resin and reacted for 2 h, protected from light. The reaction vessel was drained and the resin washed with 0.5% diethyldithiocarbamate in DMF, DMF, and CH_2Cl_2 . The Fmoc group was removed with 20% piperidine in DMF (2×10 min). Peptide cyclization was performed by treating the resin-bound linear peptide with PyBOP (5 equiv), HOAt (5 equiv), and diisopropylethylamine (10 equiv) in DMF for 2×1.5 h. The *N*-terminal Fmoc-Ile-OH was then coupled, deprotected, and acetylated as described above.

The resin was washed with DMF and CH_2Cl_2 , then dried. Concurrent side-chain deprotection and cleavage from resin were achieved by stirring the resin-bound peptide in 91.5:5:2.5:1 trifluoroacetic acid/water/triisopropylsilane/ethanedithiol for 2 h under N_2 . The cleaved resin was removed by filtration and the filtrate concentrated by a stream of N_2 . Crude peptide was precipitated with the addition of cold Et_2O , isolated, and lyophilized from 1:1 water/acetonitrile. The dry crude peptide was purified by RP-HPLC employing the gradients described below (solvent A is 0.1% trifluoroacetic acid in water; solvent B is 80% acetonitrile in water with 0.086% trifluoroacetic acid). Product-containing fractions were pooled, lyophilized, and checked for identity by MALDI-TOF MS.

Peptide 2

This compound was purified on a Waters Delta-Pak C18 preparative column with the following gradient: 2% solvent B for 1 min, 2–20% B over 2 min, 20–26% B over 3 min, 26–41% B over 30 min. After lyophilization, 8 mg of pure peptide were obtained from a 0.1-mmol-scale synthesis (5.0% total yield, 90% per step over 29 steps). $R_t = 31.9$ –32.8 min. LRMS (MALDI-TOF) calc. for $\text{C}_{72}\text{H}_{103}\text{N}_{22}\text{O}_{18}\text{S}$ 1595.7, found 1595.7.

Peptide 3

This compound was purified in the same fashion as **2**. After lyophilization, 6 mg of pure peptide were obtained from a 0.1-mmol-scale synthesis (3.8% total yield, 89% per step over 29 steps). $R_t = 31.8$ –32.8 min. LRMS (MALDI-TOF) calc. for $\text{C}_{72}\text{H}_{103}\text{N}_{22}\text{O}_{18}\text{S}$ 1595.7, found 1596.0.

Peptide 5

This compound was purified on a Phenomenex Luna C18 preparatory column with the following gradient: 5% B for 1 min, 5–24% B over 2 min, 24–30% B over 3 min, 30–45% B over 30 min. After lyophilization, 12 mg of pure peptide were obtained from a 0.3-mmol-scale synthesis (2.4% total yield, 88% per step over 29 steps). $R_t = 26.7$ –27.8 min. LRMS (MALDI-TOF) calc. for $\text{C}_{77}\text{H}_{113}\text{N}_{22}\text{O}_{17}\text{S}$ 1649.8, found 1649.9.

Synthesis of control peptides 1 and 4

The synthesis and characterization of these peptides has been described previously (41, 58).

Kinetic analyses

C3 was purified from human plasma as described before (43). C3b was generated by limited trypsinization and labeled with biotin-maleimide using established protocols (59). The interaction of the compstatin analogues with C3b was characterized using a Biacore 3000 instrument (GE Healthcare, Corp., Piscataway, NJ) at 25 °C. The running buffer was PBS, pH 7.4 (10 mM sodium phosphate, 150 mM NaCl) with 0.005% Tween-20. Biotinylated C3b was captured site-specifically on a streptavidin chip at ~3000, 4000, and 5000 RU density; an untreated flow cell was used as a reference surface. An initial kinetic ranking was performed by injecting the various peptides at a constant concentration of 1 μ M for 2 min. For detailed kinetic analysis, sets of five increasing concentrations of a particular compound were consecutively injected over the chip surface in a single cycle without waiting for full dissociation between injections (kinetic titration) (46). A three-fold dilution series (one set at 0.46–37 nM for analogues **4** and **5**, and two sets at 0.46–37 nM and 111–9000 nM for all other analogues) was injected at a flow rate of 30 μ L/min; each injection was done for 2 min, allowing the peptide to dissociate for 5 min each time before the next injection was started. After the end of the last injection, a 10-min dissociation was used for compounds **1**, **2** and **3**, while a 15-min dissociation was used for compounds **4** and **5**. The data analysis was performed using BIAevaluation. A series of blank injections was subtracted from the binding signals (double referencing) and the processed signals were fitted to a single cycle 1:1 binding model (kindly provided by GE Healthcare) to extract the kinetic rate constants (k_a , k_d) and calculate the binding affinity ($K_D = k_d/k_a$).

Complement inhibition assays

To assess the complement inhibitory ability of the compstatin analogues, an enzyme-linked immunosorbent assay (ELISA) was performed as previously described (60) with small modifications. In brief, an ovalbumin-based antigen/antibody complex was used as an initiator of the classical pathway of complement activation. Serial dilutions of the compstatin analogues were prepared, and normal human plasma was added to a final dilution of 1:80 in veronal-buffered saline containing MgCl₂ and CaCl₂ (VB⁺⁺). Incubation for 15 min followed to allow complement activation and amplification. The deposition of C3b on the plate was measured with a polyclonal antibody against C3. The percentage of inhibition was plotted against the compstatin concentration and fitted to a logistic dose-response function using Origin (OriginLab Corp., Northampton, MA).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Deborah McClellan for editorial assistance. This work was supported by the Robert C. and Carolyn J. Springborn Endowment (PJK), the Howard Hughes Medical Institute (WAV) and National Institutes of Health grants T32 GM070421 (PJK), GM062134 (JDL) and AI068730 (JDL).

References

1. Woycechowsky KJ, Raines RT. Native disulfide bond formation in proteins. *Curr Opin Chem Biol.* 2000; 4:533–539. [PubMed: 11006541]
2. Terlau H, Olivera BM. Conus venoms: A rich source of novel ion channel-targeted peptides. *Physiol Rev.* 2004; 84:41–68. [PubMed: 14715910]
3. Daly NL, Rosengren KJ, Craik DJ. Discovery, structure and biological activities of cyclotides. *Adv Drug Delivery Rev.* 2009; 61:918–930.

4. Ganz T. Defensins: Antimicrobial peptides of innate immunity. *Nat Rev Immunol.* 2003; 3:710–720. [PubMed: 12949495]
5. Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, Matsoukas J, Apostolopoulos V. Round and round we go: Cyclic peptides in disease. *Curr Med Chem.* 2006; 13:2221–2232. [PubMed: 16918350]
6. Craik DJ, Cemazar M, Daly NL. The cyclotides and related macrocyclic peptides as scaffolds in drug design. *Curr Opin Drug Discovery Dev.* 2006; 9:251–260.
7. Gehrmann J, Alewood PF, Craik DJ. Structure determination of the three disulfide bond isomers of α -conotoxin GI: A model for the role of disulfide bonds in structural stability. *J Mol Biol.* 1998; 278:401–415. [PubMed: 9571060]
8. Rabenstein DL, Weaver KH. Kinetics and equilibria of the thiol/disulfide exchange reactions of somatostatin with glutathione. *J Org Chem.* 1996; 61:7391–7397. [PubMed: 11667665]
9. Laboissiere MCA, Sturley SL, Raines RT. The essential function of protein-disulfide isomerase is to unscramble non-native disulfide bonds. *J Biol Chem.* 1995; 270:28006–28009. [PubMed: 7499282]
10. Muttenthaler M, Nevin ST, Grishin AA, Ngo ST, Choy PT, Daly NL, Hu SH, Armishaw CJ, Wang CIA, Lewis RJ, Martin JL, Noakes PG, Craik DJ, Adams DJ, Alewood PF. Solving the α -conotoxin folding problem: Efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists. *J Am Chem Soc.* 2010; 132:3514–3522. [PubMed: 20163143]
11. Armishaw CJ, Daly NL, Nevin ST, Adams DJ, Craik DJ, Alewood PF. α -Selenoconotoxins, a new class of potent α_7 neuronal nicotinic receptor antagonists. *J Biol Chem.* 2006; 281:14136–14143. [PubMed: 16500898]
12. Hargittai B, Sole NA, Groebe DR, Abramson SN, Barany G. Chemical syntheses and biological activities of lactam analogues of α -conotoxin SI. *J Med Chem.* 2000; 43:4787–4792. [PubMed: 11123987]
13. Spinella MJ, Malik AB, Everitt J, Andersen TT. Design and synthesis of a specific endothelin 1 antagonist: Effects on pulmonary vasoconstriction. *Proc Nat Acad Sci USA.* 1991; 88:7443–7446. [PubMed: 1871142]
14. Elaridi J, Patel J, Jackson WR, Robinson AJ. Controlled synthesis of (S,S)-2,7-diaminosuberic acid: A method for regioselective construction of dicarba analogues of multicystine-containing peptides. *J Org Chem.* 2006; 71:7538–7545. [PubMed: 16995657]
15. Derksen DJ, Stymiest JL, Vederas JC. Antimicrobial leucocin analogues with a disulfide bridge replaced by a carbocycle or by noncovalent interactions of allyl glycine residues. *J Am Chem Soc.* 2006; 128:14252–14253. [PubMed: 17076487]
16. Stymiest JL, Mitchell BF, Wong S, Vederas JC. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. *J Org Chem.* 2005; 70:7799–7809. [PubMed: 16277299]
17. Bondebjerg J, Grunnet M, Jespersen T, Meldal M. Solid-phase synthesis and biological activity of a thioether analogue of conotoxin G1. *ChemBioChem.* 2003; 4:186–194. [PubMed: 12616632]
18. Rew Y, Malkmus S, Svensson C, Yaksh TL, Chung NN, Schiller PW, Cassel JA, DeHaven RN, Goodman M. Synthesis and biological activities of cyclic lanthionine enkephalin analogues: Delta-opioid receptor selective ligands. *J Med Chem.* 2002; 45:3746–3754. [PubMed: 12166947]
19. Jost K, Prochazka Z, Cort JH, Barth T, Skopkova J, Prusik Z, Sorm F. Amino acids and peptides. CXXII Synthesis and some biological activities of analogs of deaminovasopressin with the disulfide bridge altered to a thioether bridge. *Collect Czech Chem Commun.* 1974; 39:2835–2856.
20. Mayer JP, Heil JR, Zhang J, Munson MC. An alternative solid-phase approach to C1-oxytocin. *Tetrahedron Lett.* 1995; 36:7387–7390.
21. Jones DS, Gamino CA, Randow ME, Victoria EJ, Yu L, Coutts SM. Synthesis of a cyclic-thioether peptide which binds anti-cardiolipin antibodies. *Tetrahedron Lett.* 1998; 39:6107–6110.
22. Fotouhi N, Joshi P, Tilley JW, Rowan K, Schwinge V, Wolitzky B. Cyclic thioether peptide mimetics as VCAM-VLA-4 antagonists. *Bioorg Med Chem Lett.* 2000; 10:1167–1169. [PubMed: 10866373]
23. Willey JM, van der Donk WA. Lantibiotics: Peptides of diverse structure and function. *Ann Rev Microbiol.* 2007; 61:477–501. [PubMed: 17506681]

24. Paul M, van der Donk WA. Chemical and enzymatic synthesis of lanthionines. *Mini-Rev Org Chem.* 2005; 2:23.
25. Ross AC, Liu H, Pattabiraman VR, Vederas JC. Synthesis of the lantibiotic lactocin S using peptide cyclizations on solid phase. *J Am Chem Soc.* 2010; 132:462–463. [PubMed: 20017553]
26. Pattabiraman VR, McKinnie SMK, Vederas JC. Solid-supported synthesis and biological evaluation of the lantibiotic peptide bis(desmethyl) lactacin 3147 A2. *Angew Chem Int Ed.* 2008; 47:9472–9475.
27. Bregant S, Tabor AB. Orthogonally protected lanthionines: Synthesis and use for the solid-phase synthesis of an analogue of nisin ring C. *J Org Chem.* 2005; 70:2430–2438. [PubMed: 15787528]
28. Matteucci M, Bhalay G, Bradley M. Cystine mimetics--solid phase lanthionine synthesis. *Tetrahedron Lett.* 2004; 45:1399–1401.
29. Zhou H, van der Donk WA. Biomimetic stereoselective formation of methylanthionine. *Org Lett.* 2002; 4:1335–1338. [PubMed: 11950356]
30. Burrage S, Raynham T, Williams G, Essex JW, Allen C, Cardno M, Swali V, Bradley M. Biomimetic synthesis of lantibiotics. *Chem Eur J.* 2000; 6:1455–1466.
31. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. Angiotensin-(1–7) with thioether bridge: An angiotensin-converting enzyme-resistant, potent angiotensin-(1–7) analog. *J Pharmacol Exp Ther.* 2009; 328:849–854. [PubMed: 19038778]
32. Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, Nelemans SA, Akanbi MHJ, Moll GN. To protect peptide pharmaceuticals against peptidases. *J Pharmacol Toxicol Methods.* 2010; 61:210–218. [PubMed: 20176117]
33. Osapay G, Prokai L, Kim HS, Medzihradsky KF, Coy DH, Liapakis G, Reisine T, Melacini G, Zhu Q, Wang SHH, Mattern RH, Goodman M. Lanthionine-somatostatin analogs: Synthesis, characterization, riological activity, and enzymatic stability studies. *J Med Chem.* 1997; 40:2241–2251. [PubMed: 9216843]
34. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. *J Immunol.* 1996; 157:884–891. [PubMed: 8752942]
35. Ricklin D, Lambris JD. Compstatin: A complement inhibitor on its way to clinical application. *Adv Exp Med Biol.* 2008; 632:273. [PubMed: 19025129]
36. Janssen BJC, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. *J Biol Chem.* 2007; 282:29241–29247. [PubMed: 17684013]
37. Soulika AM, Holland MCH, Sfyroera G, Sahu A, Lambris JD. Compstatin inhibits complement activation by binding to the β -chain of complement factor 3. *Mol Immunol.* 2006; 43:2023–2029. [PubMed: 16472861]
38. Ricklin D, Lambris JD. Complement-targeted therapeutics. *Nat Biotechnol.* 2007; 25:1265–1275. [PubMed: 17989689]
39. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration. *Nat Rev Drug Discov.* 2009; 8:922–922.
40. Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. *J Immunol.* 2000; 165:2491–2499. [PubMed: 10946275]
41. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. *Mol Immunol.* 2011; 48:481–489. [PubMed: 21067811]
42. Magotti P, Ricklin D, Qu H, Wu YQ, Kaznessis YN, Lambris JD. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. *J Mol Recognit.* 2009; 22:495–505. [PubMed: 19658192]
43. Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. *J Med Chem.* 2006; 49:4616–4622. [PubMed: 16854067]

44. Zhu X, Schmidt RR. Efficient synthesis of differently protected lanthionines via beta-bromoalanine derivatives. *Eur J Org Chem.* 2003; 2003:4069–4072.
45. Küsters E, Allgaier H, Jung G, Bayer E. Resolution of sulphur-containing amino acids by chiral phase gas chromatography. *Chromatographia.* 1984; 18:287–293.
46. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszkowski DG. Analyzing a kinetic titration series using affinity biosensors. *Anal Biochem.* 2006; 349:136–147. [PubMed: 16337141]
47. Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB, Kinasevitz G, Lambris JD, Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of *Escherichia coli* sepsis. *Blood.* 2010; 116:1002–1010. [PubMed: 20466856]
48. Leaver SK, MacCallum NS, Pingle V, Hacking MB, Quinlan GJ, Evans TW, Burke-Gaffney A. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. *Intensive Care Med.* 2010; 36:336–341. [PubMed: 19756498]
49. Kourtzelis I, Markiewski MM, Dumas M, Rafail S, Kambas K, Mitroulis I, Panagoutsos S, Passadakis P, Vargemelis V, Magotti P, Qu H, Mollnes TE, Ritis K, Lambris JD. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. *Blood.* 2010; 116:631–639. [PubMed: 20424189]
50. Serru V, Baudin B, Ziegler F, David JP, Cals MJ, Vaubourdoille M, Mario N. Quantification of reduced and oxidized glutathione in whole blood samples by capillary electrophoresis. *Clin Chem.* 2001; 47:1321–1324. [PubMed: 11427471]
51. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. Interference of plasmatic reduced glutathione and hemolysis on glutathione disulfide levels in human blood. *Free Radic Res.* 2004; 38:1101–1106. [PubMed: 15512798]
52. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: An update. *Pharm Res.* 2010; 27:544–575. [PubMed: 20143256]
53. Davies MJ. The oxidative environment and protein damage. *Biochim Biophys Acta, Proteins Proteomics.* 2005; 1703:93–109.
54. Wilson-Stanford S, Kalli A, Hakansson K, Kastrantas J, Orugunty RS, Smith L. Oxidation of lanthionines renders the lantibiotic nisin inactive. *Appl Environ Microbiol.* 2009; 75:1381–1387. [PubMed: 19114522]
55. Boakes S, Cortés J, Appleyard AN, Rudd BAM, Dawson MJ. Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. *Mol Microbiol.* 2009; 72:1126–1136. [PubMed: 19400806]
56. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: Science and market. *Drug Discovery Today.* 2010; 15:40–56. [PubMed: 19879957]
57. Stevenson CL. Advances in peptide pharmaceuticals. *Curr Pharm Biotechnol.* 2009; 10:122–137. [PubMed: 19149594]
58. Katragadda M, Morikis D, Lambris JD. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin. *J Biol Chem.* 2004; 279:54987–54995. [PubMed: 15489226]
59. Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. *J Immunol.* 2001; 167:1490–1499. [PubMed: 11466369]
60. Mallik B, Katragadda M, Spruce LA, Carafides C, Tsokos CG, Morikis D, Lambris JD. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. *J Med Chem.* 2005; 48:274–286. [PubMed: 15634022]

Figure 1.

Complement-targeted inhibitory mechanism and peptide sequences of compstatin analogues. (a) The complement cascade is initiated through at least three different mechanisms, which all converge in the proteolytic activation of C3 to C3b; C3b participates in a self-amplified loop that enhances the effect of complement activation. Inhibition by compstatin at the level of C3/C3b effectively stops the activation of all initiation pathways, the amplification loop and all downstream effects of complement activation. C1-C5: complement components 1–5; FB: factor B; FD: factor D; MAC: membrane attack complex; MBL: mannose-binding lectin; MASP: MBL-associated serine protease; P: properdin. (b) The sequences of compstatin analogues **1–5** used in this study. The two cystathionine isomers are depicted as Ala-Hcy or Hcy-Ala, depending on the position of the sulfur atom. Hcy: homocysteine; Trp(Me): 1-methyltryptophan.

Figure 2. Kinetic ranking of compstatin analogues. (a) 1 μ M of peptide was injected over captured C3b at a surface density of 3000 RU. The signals are overlaid to show relative differences in their association and dissociation phases. Each plot is a representative of three data sets. RU: resonance units. (b) Schematic representation of the SPR assay.

Figure 3.

Single-cycle kinetics analysis of the thioether compstatin analogues and corresponding disulfide bond controls. Sets of five increasing concentrations were consecutively injected over a C3b surface (3000 RU density) in a single cycle. In the case of peptides 1–3, two sets of concentrations are superimposed for a better description of the full binding range and to achieve a well-defined affinity profile. The processed signals were fitted to a 1:1 binding model (orange simulation curves) and kinetic rate constants k_a and k_d were extracted (Table 1). The compstatin analogue used is shown in the top left corner of each plot. Plots show representatives of at least six data sets.

Figure 4. Inhibitory activity of compstatin analogues. (a) Representative assay result for inhibition of antigen/antibody complex-initiated complement activation by compstatin analogues. The percentage inhibition is plotted against the peptide concentration and compared to that for parent compstatin analogues **1** and **4**. Plots show a representative of at least five assays. BSA: bovine serum albumin; OVA: ovalbumin; a-hC3 HRP: anti-human C3 antibody conjugated to horseradish peroxidase. (b) Schematic representation of the assay.

^a Reagents and conditions: a) 70% HClO₄, ^tBuOAc; b) Fmoc-OSu, *N*-methylmorpholine, THF, 62% (two steps); c) PBu₃, H₂O, THF, 86%; d) Alloc-Cl, Na₂CO₃, H₂O, CH₃CN; e) allyl bromide, NaHCO₃, DMF, 77% (two steps); f) PPh₃, CBr₄, CH₂Cl₂, 80%; g) Bu₄NBr, NaHCO₃, H₂O, EtOAc, 84%; h) CF₃CO₂H, PhSiH₃, CH₂Cl₂, 95%.

Scheme 2.

Synthesis of Fmoc-cystathionine isomer **17**.^a

^a Reagents and conditions: a) Fmoc-OSu, Na₂CO₃, H₂O, 1,4-dioxane; b) CCl₃C(NH)O^tBu, CH₂Cl₂, THF, 52% (two steps); c) PPh₃, CBr₄, CH₂Cl₂, 94%; d) Aloc-Cl, Na₂CO₃, H₂O, CH₃CN; e) allyl bromide, NaHCO₃, DMF, 70% (two steps); f) CF₃CO₂H, ^tPr₃SiH, CH₂Cl₂, 85%; g) Bu₄NBr, NaHCO₃, H₂O, EtOAc, 93%; h) CF₃CO₂H, PhSiH₃, CH₂Cl₂, 98%.

Scheme 3.

Synthesis of cystathionine-containing compstatin analogues **2**, **3** and **5**.^{a,b}

^a Reagents and conditions: a) SPPS; b) Pd(PPh₃)₄, PhSiH₃, DMF; c) piperidine, DMF; d) PyBOP, HOAt, ⁱPr₂EtN, DMF; e) CF₃CO₂H, H₂O, ⁱPr₃SiH, HS(CH₂)₂SH. ^b An asterisk indicates standard Fmoc-orthogonal side chain protection: Gln(Trt), Asp(O^tBu), Trp(Boc), His(Trt), Arg(Pbf), Thr(^tBu).

Table 1

Kinetic rate constants, binding affinities, inhibitory potential and relative inhibitory activities (rIC₅₀) of compstatin analogues.

Peptide	k_a (10^5 M ⁻¹ s ⁻¹) ^a	k_d (10^{-2} s ⁻¹) ^a	K_D (nM) ^a	IC ₅₀ (nM) ^b	rIC ₅₀
1	5.6 ± 1.4	8.1 ± 1.1	150 ± 19	1900 ± 1200	1
2	5.5 ± 0.7	46.8 ± 5.7	847 ± 59	> 20000	> 10
3	4.6 ± 0.5	11 ± 1.9	236 ± 20	3100 ± 1800	1.6
4	18.6 ± 4.1	0.4 ± 0.1	2.4 ± 0.6	130 ± 40	1
5	16.4 ± 3.8	1.5 ± 0.4	9 ± 1.8	270 ± 80	2.1

^a Results show average and standard deviations of at least six data sets.

^b Results show average and standard deviations of at least five data sets.